In Vitro Efficacy Testing Services for Malaria

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for malaria. Our services enable precise assessment of compound efficacy against Plasmodium species, the causative agents of malaria. Key molecular targets include Plasmodium falciparum enzymes, transporters, and metabolic pathways essential for parasite survival and replication. We can evaluate inhibition of parasite growth, disruption of metabolic activity, and other pathological processes associated with malaria infection.

Our malaria in vitro efficacy testing utilizes advanced chemiluminescent assays designed to quantitatively measure parasite viability and drug response. These methods provide reliable and reproducible data to support the prioritization of candidate compounds in early-stage drug discovery. The overall purpose is to identify promising antimalarial agents and characterize their pharmacological profiles.

Chemiluminescent assay: This sensitive and high-throughput method measures luminescence as an indicator of parasite viability or metabolic activity in response to test compounds. It enables rapid quantification of antimalarial activity and supports screening of large compound libraries.

We measure key pharmacological parameters that reflect the potency and efficacy of candidate antimalarial compounds. These parameters are critical for ranking compounds, guiding dose selection, and informing subsequent in vivo studies. Accurate parameter determination ensures that only the most promising candidates advance in the drug development pipeline.

MEC (Minimum Effective Concentration): The lowest concentration of a compound that produces a defined level of antimalarial effect in vitro. MEC is essential for comparing compound potencies, optimizing lead selection, and establishing preliminary efficacy benchmarks.

Recommended In Vitro Efficacy Tests

Tumor Protein P53

Tumor Protein P53 plays a crucial role in host cell response to malaria infection, influencing parasite survival and drug efficacy. Testing P53 activity is vital for understanding drug mechanisms and optimizing antimalarial therapies. Our service utilizes a chemiluminescent assay to quantitatively assess P53 levels, with Minimum Effective Concentration (MEC) as a key parameter, ensuring precise evaluation of candidate drugs’ effects on P53-mediated pathways during malaria drug development.